Why JPMorgan’s $466 Price Target Makes UnitedHealth (UNH) a Top Healthcare Pick Right Now

Key Takeaways

• JPMorgan upgraded UNH price target to $466 from $420, maintaining “overweight” stance
• Mizuho increased its target to $460 from $440, keeping “outperform” recommendation
• Stock reached fresh 52-week peak near $413 on June 9, climbing over 20% year-to-date in 2026
• First quarter 2026 results exceeded projections with $111.7B revenue and $7.23 adjusted EPS
• Medical care ratio declined to 83.9% from prior year’s 84.8%, boosting margin outlook

UnitedHealth Group (UNH) finished trading at $407.73 on June 10, retreating 1.28% from the prior session, yet remaining close to its yearly peak following a series of positive analyst revisions earlier that week.

UnitedHealth Group Incorporated, UNH

On June 8, JPMorgan boosted its UNH price objective to $466 from $420, while reaffirming an “overweight” designation. This mark now represents the most aggressive target among major Wall Street firms, implying approximately 14% upside from the stock’s trading level at that moment.

Shortly after, Mizuho announced its own revision—elevating its price goal to $460 from $440 and preserving an “outperform” recommendation.

Mizuho informed investors that the managed care industry is entering a period of greater regulatory stability. Unexpected policy shifts from federal agencies have diminished following three turbulent years, creating a more predictable operating environment.

Shares touched a new 52-week pinnacle around $413 on June 9, advancing more than 20% through the first half of 2026.

Last Year’s Troubles Created Today’s Opportunity

To grasp why Wall Street has turned this optimistic, it’s essential to recall how challenging 2025 became.

In May 2025, CEO Andrew Witty departed unexpectedly. The board reinstated former leader Stephen Hemsley. The company withdrew its 2025 financial guidance as medical expenses exceeded internal projections.

Compounding matters, the Justice Department initiated an investigation into UnitedHealth’s Medicare reimbursement procedures. That inquiry continues.

Investors reacted by aggressively selling shares. UNH dropped to approximately $300–$312 per share—a steep decline from its record closing price of $603.20 reached in November 2024. Berkshire Hathaway established a position around $271 during the selloff, then liquidated the entire stake during Q1 2026.

The 2026 Turnaround Story

First quarter 2026 financial results catalyzed the recovery. UnitedHealth delivered revenue of $111.7 billion and adjusted earnings per share of $7.23, surpassing analyst expectations. The stock surged more than 8% following the announcement.

The metric that truly shifted sentiment was the medical care ratio—representing the percentage of premium income allocated to medical claims. It improved to 83.9% from 84.8% in the comparable period. A lower ratio means the organization retains a larger portion of revenue as operating profit. This enhancement restored institutional confidence more effectively than any executive presentation.

Consensus forecasts from Zacks for Q2 anticipate $4.84 earnings per share and $110.05 billion in revenue. Full-year projections call for $18.32 EPS and $443.7 billion in revenue, suggesting approximately 12% annual earnings expansion.

UNH presently commands a forward price-to-earnings multiple of 22.55, exceeding the sector average of 19.11.

JPMorgan’s optimistic outlook depends on three favorable developments: the DOJ Medicare inquiry concluding without substantial monetary sanctions, medical cost trends continuing their downward trajectory, and leadership executing on its 13%–16% long-term expansion objectives.

Berkshire’s decision to exit—disposing of shares acquired near cycle lows relatively quickly—represents a noteworthy detail certain market participants are monitoring.

The Medical-HMOs sector currently maintains a Zacks Industry Rank of 25, positioning it within the top 11% of all monitored industries.

The post Why JPMorgan’s $466 Price Target Makes UnitedHealth (UNH) a Top Healthcare Pick Right Now appeared first on Blockonomi.